Redx Pharma Plc (REDX.L) Announced that it has signed a definitive agreement with Jazz Pharmaceuticals plc (Jazz) under which Jazz has acquired the company’s pan-RAF inhibitor programme for the potential treatment of RAF and RAS mutant tumours. Jazz will be responsible for all future development, regulatory, manufacturing and commercialisation activities. Under the terms of the agreement, Jazz will pay an upfront payment of $3.5 million in cash for all rights, title and interest relating to the company’s proprietary pan-RAF inhibitor programme, including all related patents. The company is eligible to receive up to $203 million in development, regulatory and commercial milestone payments from Jazz, with the next milestones being initiation of IND enabling studies, followed by a further milestone at IND submission to the FDA. It is also eligible for incremental tiered royalties in mid-single digit percentage, based on any future net sales.
Redx Pharma (REDX.L) 14.5p £7.9m Redx Pharma announced that it has signed a definitive agreement with Jazz Pharmaceuticals plc (Nasdaq: JAZZ; "Jazz") under which Jazz has acquired Redx's pan-RAF inhibitor programme for the potential treatment of RAF and RAS mutant tumours. Jazz will be responsible for all future development, regulatory, manufacturing and commercialisation activities. Under the terms of the agreement, Jazz will pay Redx an upfront payment of $3.5 million in cash for all rights, title and interest relating to Redx's proprietary pan-RAF inhibitor programme, including all related patents. Redx is eligible to receive up to $203m in development, regulatory and commercial milestone payments from Jazz, with the next milestones being initiation of IND enabling studies, followed by a further milestone at IND submission to the FDA. Redx is also eligible for incremental tiered royalties in mid-single digit percentage, based on any future net sales. As part of a separate collaboration agreement, signed in parallel, Jazz will pay Redx to perform research and preclinical development services with the goal of completing IND-enabling studies.
Redx to receive $3.5 million upfront, up to $203 million in milestone payments and royalty payments. Under the terms of the agreement, Jazz will pay Redx an upfront payment of $3.5 million in cash for all rights, title and interest relating to Redx's proprietary pan-RAF inhibitor programme, including all related patents. Redx is eligible to receive up to $203...
REDX Pharma (REDX.L) 5.25p £6.64m FY mar 19 results from the drug discovery and development Group. “In our 2018 annual report the Board and Management set out our strategy, focused on moving RXC004, our porcupine inhibitor programme for Wnt driven cancer, back into the clinic. We also set out our plan to move RXC006, a porcupine inhibitor targeted at idiopathic pulmonary fibrosis, into preclinical development as well as selecting a development candidate for our ROCK2 programme for fibrosis. Throughout the first six months of the year we have made progress against these aims, most notably reinitiating our phase 1 clinical trial of RXC004 .” “Short-term loan agreement of up to £2.5m from Moulton Goodies Ltd (MGL), the Company's largest shareholder, which extends our cash runway into the fourth quarter of 2019.”
Redx Pharma Plc (REDX.L) Announced, in its interim results for the six months ended 31 March 2019, that its loss from operations stood at £4.05 million, compared to £4.96 million in the preceding year. The company’s diluted loss per share was 1.8p, compared to 3.6p. Separately, the company announced that it has signed an agreement with Moulton Goodies Ltd. for a fixed rate secured loan note facility of up to £2.5 million.
RNS Number: 6020 B Redx Pharma plc 10 June 2019 REDX PHARMA PLC. Today, we announced that we have signed a short-term loan agreement of up to £2.5 million from Moulton Goodies Ltd, the Company's largest shareholder, which extends our cash runway into the fourth quarter of 2019. We continue to be in active discussions with shareholders and third-party healthcare...
RNS Number: 6015 B Redx Pharma plc 10 June 2019 THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION. Further to the announcement released on 3 May 2019, the Board is pleased to announce that the Company has signed an agreement with Moulton Goodies Ltd....
RNS Number: 0494 Y Redx Pharma plc 03 May 2019 THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION. UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Redx Pharma Plc (REDX.L) Announced that the two abstracts submitted by the company have been accepted for presentation as posters at the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta, Georgia, taking place between 29 March and 3 April 2019. Both posters relate to the company's lead oncology candidate, RXC004, a selective, orally bioavailable porcupine (PORCN) inhibitor which targets the Wnt signalling pathway. The posters present preclinical data confirming the potential for RXC004 in modulating the immune system of the tumour microenvironment (poster #506) as well as preclinical data on the direct tumour-targeting effects of RXC004 in genetically-defined models of cancer.
RNS Number: 3986 U Redx Pharma plc 29 March 2019 REDX PHARMA PLC. Redx Pharma to present two posters at the 2019 American Association for Cancer Research Annual Meeting. Alderley Park, 29 March 2019- Redx Pharma, the drug discovery and development company focused on cancer and fibrosis, announces that the two abstracts submitted by the Company have been accepted...
RNS Number: 3457 R Redx Pharma plc 28 February 2019 THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION. Alderley Park, 28 February 2019 Redx, the drug discovery and development company focused on cancer and fibrosis, announces that, as previously...
Redx Pharma Plc (REDX.L) Announced that James Mead assumed his new role as Chief Financial Officer on 1 February 2019 and has become a member of the company's Board of Directors.
RNS Number: 9568 P Redx Pharma plc 14 February 2019 REDX PHARMA PLC. Redx announces directorate update and grant of options. Redx is a UK biotechnology Group whose shares are traded on AIM.
RNS Number: 6903 P Redx Pharma plc 12 February 2019 THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION. UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
RNS Number: 2669 P Redx Pharma plc 06 February 2019 THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION. UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
RNS Number: 5701 O Redx Pharma plc 31 January 2019 REDX PHARMA PLC. Last week, the Company announced that the UK's Medicines and Healthcare products Regulatory Agency has given formal approval to the Company to re-commence the phase 1/ 2 a trial for RXC004, an oral porcupine inhibitor targeting the Wnt signalling pathway. Redx is a UK based biotechnology company...
RNS Number: 9033 N Redx Pharma plc 23 January 2019 REDX PHARMA PLC. Redx is a UK based biotechnology company whose shares are traded on AIM. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Redx Pharma Plc
REDX.L
Redx Pharma Plc
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    126.48M

Company Profile

Redx Pharma discovers and develops proprietary, small molecule drugs to address areas of high unmet medical need in cancer and fibrosis. In cancer, we pursue targeted therapies where a biomarker can potentially be used for selecting those patients that are most likely to benefit from therapy, and/or drugs that are designed to disrupt cancer resistance pathways. In fibrosis, we are focused on developing treatments that will stop and reverse the formation of fibrotic tissue. In both therapeutic areas we aim to develop drugs whose profile suggests they will be best in class, if not first in class.

Classification

Market Indices-

Locations

HQ
Alderley Park
Mereside
Block 33
Macclesfield
SK10 4TG
Watchlist